None listed
Conditions
Brief summary
This study aims to compare the effect of a single bout of exercise on endocannabinoid (eCB) and affective (mood) responses in adults with cancer currently receiving chemotherapy treatment versus their healthy peers, and to evaluate relationships between eCB and mood responses to exercise. Who is this study for? You may be eligible for this study if you are a cancer patient aged 18 or older, and currently receiving chemotherapy treatment; and if you are an apparently healthy adult (age 18+) . Study details All participants will engage in a single testing session involving seated rest (30 min) followed by a moderate exercise bout on treadmill or exercise cycle (30 min). Participants will be asked to fill in mood surveys and provide blood samples before and after the seated rest and exercise conditions. It is hoped that findings from this study will help inform future trials investigating the benefits and barriers to exercise in cancer patients.
Interventions
Acute Exercise (30 min) will be performed immediately following the control condition:
Each participant will perform one acute aerobic exercise bout on self-selected equipment modality (Precor treadmill, Precor upright cycle or Monark RT2 recumbent cycle ergometer) and aim to attain a moderate intensity (i.e. 64-76% of age-predicted maximal heart rate (HRmax=208 – (0.7 × age)) within 5 min (warm-up) and then maintain this HR intensity range (64-76% of HRmax) for 20 minutes continuously. For the
Acute Exercise (30 min) will be performed immediately following the control condition: Each participant will perform one acute aerobic exercise bout on self-selected equipment modality (Precor treadmill, Precor upright cycle or Monark RT2 recumbent cycle ergometer) and aim to attain a moderate intensity (i.e. 64-76% of age-predicted maximal heart rate (HRmax=208 – (0.7 × age)) within 5 min (warm-up) and then maintain this HR intensity range (64-76% of HRmax) for 20 minutes continuously. For the final 5 min, participants will perform a cool-down with the aim of reducing heart rate to below 60% of by the end of the 30 min condition. Rating of perceived exertion (RPE), heart rate and SpO2 will be collected at 1 min intervals throughout the exercise condition. Heart rate will be measured via a Polar H9/H10 heart rate monitor (Polar Electro Oy, Professorintie 5, Fi-90440 Kempele, Finland) and Oxygen saturation will be recorded via iHealth pulse oximeter. Blood pressure will be collected every 5 min via a manual Welsh Allyn DS66 trigger aneroid sphygmomanometer using the non-cannulated arm unless contraindicated (e.g. lymphedema risk). Exercise does not stop for the collection of any data. Recommended criteria for prematurely terminating the exercise condition will be adhered to, as defined by the American College of Sports Medicine. At the end of the exercise bout, the third and final blood sample being collected and then the ten VAS scales will be re-assessed, followed by a question asking participants whether they had experienced a ‘Runner’s high’ (Yes / No / I don’t know), as implemented in a previous trial.
Sponsors
Chris O'Brien Lifehouse
Study design
Allocation
Non-randomised trial
Primary purpose
Treatment
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
Cancer patients: Adults (18 years and older) commenced chemotherapy treatment for a non-haematological cancer with a 2 or 3-weekly protocol; Eastern Cooperative Oncology Group (ECOG) performance status of 0–1, medical approval of the treating oncologist (via email), sufficient English to provide consent and complete study procedures. Healthy controls: Adults (>18 years); gender-, age- (+/-5 years maximum) and BMI-matched (+/-3.5 kg/m2 maximum) to the recruited cancer patient; no history of systemic cancer treatment; no history of cardiac, metabolic, pulmonary, neurological and/or uncontrolled risk factors; sufficient English to provide consent and complete study procedures.
Exclusion criteria
• currently using cannabis regularly, for any reason • any use of cannabis or cannabis products (e.g. CBD oil) within the previous 72 hours • vigorous exercise or use of complementary therapies such as acupuncture, massage, reflexology, yoga or mindfulness training within 24 hours of the research session • currently using anti-depressant and/or anxiolytic medication • continuous use of steroids (i.e. outside of their standard chemotherapy protocol in cancer patients) • presenting with any absolute or relative contraindication to clinical exercise testing, as defined by the American College of Sports Medicine.
Outcome results
None listed